<DOC>
	<DOCNO>NCT02473133</DOCNO>
	<brief_summary>In patient locally advanced stage III non-small cell lung cancer , probability local control remain low ( 17 % 1 year ) . Concomitant radio-chemotherapy standard treatment . An increase total radiotherapy dose ( 66 74 Gray ) propose improve local control , contradictory result . Relevant FDG-PET scan image acquire radio-chemotherapy , demonstrate prognostic impact recently multicentre prospective study . A significant reduction FDG uptake / volume ( metabolic response ) suggest radiotherapy target volume could reduce radiotherapy possibly improve organ risk tolerance . Conversely , lack metabolic response may justify treatment intensification end radiotherapy . The investigator hypothesis investigate individual tumour heterogeneity FDG-PET radio-chemotherapy reduce volume biological target could receive high total dose ( personalize dose redistribution ) .</brief_summary>
	<brief_title>Study Interest Personalized Radiotherapy Dose Redistribution Patients With Stage III NSCLC</brief_title>
	<detailed_description>The investigator objective determine whether tumour radiotherapy dose escalate 74 Gy 6.6 week improve disease Local Regional Control rate 15 month ( 1 year completion RCT ) adapt radiotherapy target volume metabolic response assess FDG-PET/CT perform 42 Gy concomitant radio-chemotherapy stage III non-small cell lung cancer warrant extensive phase III study . Eligible patient allocate one 2 treatment group : - Arm A : Patients experimental arm receive individualize radiotherapy prescription total dose 74 Gy give 6.6 week positive FDG-PET 42Gy . - Arm B : Patients standard arm receive single prescription 66 Gy 33 fraction 6.6 week , 2 Gy fraction give daily , 5 day week , without target volume reduction adaptation ( whatever FDG-PET result ) . In arm , patient undergo 2 cycle induction chemotherapy ( base platinum salt ) curative radio-chemotherapy . In arms field must treat daily .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Male female patient , Age 18 year 75yearold , Good general condition : WHO performance status ≤ 1 , Histological evidence nonsmall cell lung cancer , Measureable tumour accord RECIST 1.1 evaluation criterion , Mediastinoscopy endobronchial ultrasound prove histological stage N2/N3 , Patient eligible curativeintent radiochemotherapy , Absence pleural involvement , pulmonary extrathoracic metastatic localisation , Absence comorbidity contraindicate radiochemotherapy , Lung function : FEV1 ≥ 40 % theoretical value DLCO/VA ≥ 60 % theoretical value PaO2 ≥ 60 mm Hg , Tumour FDG uptake high mediastinal background noise baseline PET/CT , Haematological parameter : Neutrophil count ≥ 1.5x109/L platelet count ≥ 100x109/L , Haemoglobin ≥ 9 g/dL , Provisional RT plan confirm dose objective ( minimal dose 62.7 Gy ( 95 % prescribe dose ) 98 % target volumes 70.3 Gy `` boost '' volume 74 Gy ) constraint ( lung , spinal cord ) meet ( ICRU83 ) , Estimated creatinine clearance ≥ 60 mL/min , Signed informed consent Affiliated beneficiary social benefit system Histology nonsmall cell lung cancer , Absence FDG uptake FDGPET/CT scan induction chemotherapy , Patients curative radiotherapy indicate ( tumour extension , metastasis , general condition , comorbidities ) , Significant interstitial disease CT scan , Previous neoplastic disease le 5 year duration progressive ( without basal cell carcinoma skin , situ carcinoma cervix ) , Previous thoracic radiotherapy , Patient enrol another therapeutic trial , Pregnant woman woman childbearing potential breast feeding mother , Adult subject protective custody guardianship , Patient unable comply specific obligation study ( geographic , social physical reason ) , Uncontrolled diabetes blood glucose ≥10 mmol/L , Hypersensitivity active substance ( FDG ) excipients , Patients unable understand purpose study ( language , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>dose redistribution</keyword>
	<keyword>boost</keyword>
</DOC>